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Three new sterol sulfates, spheciosterol sulfates A-C( 1-3), and the known sterol sulfate topsentiasterol sulfate E (4)
have been isolated from the sponge Spheciospongia sp., collected in the Philippines. Structures were assigned on the
basis of extensive 1D and 2D NMR studies as well as analysis by HRESIMS. Compounds 1-4 inhibited PKC  with
IC50 values of 1.59, 0.53, 0.11, and 1.21 µM, respectively. In a cell-based assay, 1-4 also inhibited NF-κB activation
with EC50 values of 12-64 µM.
Marine organisms are widely known for producing a variety of
polyoxygenated
1 and polysulfated steroids with unusual, modiﬁed
side chains.
2 Sulfated sterols isolated from sponges have received
a considerable amount of attention due to their attractive biological
activities, particularly against HIV-1.
3–5
Members of the protein kinase C (PKC) family of serine/
threonine kinases are involved in a wide range of cellular functions
including proliferation, gene expression, cell cycle control, cell
migration, mitogenic signaling, cytoskeleton function, glucose
metabolism, differentiation, and regulation of cell survival and
apoptosis.
6,7 PKCs also play a central role in coordination of cross
talk between major signaling pathways.
6 PKC has been implicated
in the progression of numerous diseases, which makes PKC
inhibitors attractive therapeutic agents.
8 In fact, inhibitors of PKCs
are currently being tested in clinical trials for various disorders.
9
At least 11 closely related PKC isoforms have been reported that
differ in structure, biochemical properties, tissue distribution,
subcellular localization, and substrate speciﬁcity. PKC isoforms are
classiﬁed as conventional (R,  1,  2, γ), novel (δ, ε, η, θ, µ), and
atypical ( , λ/ι).
7 Conventional PKCs are regulated by diacylglyc-
erol, phosphatidylserine, and calcium. Novel PKCs are regulated
by diacylglycerol and phosphatidylserine, but are calcium inde-
pendent. Atypical PKC isoforms are phosphatidylserine-dependent,
but are not affected by calcium, diacylglycerols, or phorbol esters.
6
Atypical PKCs have been implicated in the establishment of cell
polarity, cell proliferation, and cell survival.
10 PKC  and PKCι
exhibit 72% sequence homology at the amino acid level, but recent
data suggest their functions are not overlapped.
10 Expression
proﬁling demonstrated that PKC  and PKCι exhibit distinct patterns
of expression in various tissues and cell types; PKCι is ubiquitously
expressed, whereas PKC  exhibits a much more restricted pattern
of expression.
11 Also, genetic disruption of the PKC  and PKCι/λ
genes has very different effects on the embryonic development of
the mouse. Knockouts of PKCι/λ are embryonically lethal, whereas
knockouts of PKC  result in viable mice that exhibit only subtle
immunological deﬁciencies.
10 Finally, PKC  and PKCι/λ prefer-
entially couple to distinct downstream signaling pathways. Using
mouse embryo ﬁbroblasts generated from either PKC  or PKCι
knockout mice, it has been shown that PKC  couples more
efﬁciently to the NF-κB pathway, a well-characterized downstream
effector pathway of atypcial PKCs, than does PKCι/λ. Thus PKC -
deﬁcient ﬁbroblasts exhibit defects in NF-κB signaling, whereas
PKCι/λ-deﬁcient ﬁbroblasts do not.
10
PKC  alone has been implicated as an important factor in several
types of cancer
12–15 as well as osteoarthritis.
7,16 Therefore, PKC 
inhibitors could be beneﬁcial in a number of diseases and disorders.
As part of an ongoing search for bioactive marine metabolites,
crude extracts from our marine invertebrate library were screened
for PKC  activity. The methanol extracts of a Spheciospongia sp.,
collected in Cagayan de Oro, Philippines, showed promising activity
in the initial screen. Three new sulfated sterols, spheciosterol
sulfates A-C( 1-3), as well as the known sulfated sterol topsen-
tiasterol sulfate E (4), were isolated from this sponge. The pure
compounds, spheciosterol sulfates A-C( 1-3) and topsentiasterol
sulfate E (4), were active against PKC  and inhibited NF-κB
activation.
Results and Discussion
The specimen (CDO-00-12-141) of Spheciospongia sp. was
exhaustively extracted with MeOH. The crude extract was separated
on an HP20SS resin using a step gradient of H2O to IPA (25%
steps, 5 fractions). Bioassay-guided fractionation of the third fraction
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resulted in the isolation of spheciosterol sulfates A-C( 1-3) and
topsentiasterol sulfate E (4).
The molecular formula for spheciosterol sulfate A (1),
C30H47O13S3Na3, was derived from NMR data and the HRESIMS
ion at m/z 757.1984 ([M - Na]-, ∆ +1.3 ppm). The presence of
multiply charged ions and characteristic losses of 80 Da in MS/
MS experiments indicated the presence of sulfate esters in 1. The
structure of spheciosterol sulfate A (1) was established on the basis
of extensive 1D and 2D NMR studies. Initial interpretation of the
1H and 13C NMR data (Table 1) indicated that 1 contained four
methyl singlets (δ 0.70, 0.80, 1.42, 1.57), one methyl doublet (δ
0.89), one methyl triplet (δ 0.82), four oxygenated methines (δ
4.96, 4.84, 4.83, 4.46), a terminal oleﬁn (δ 4.75, 4.66), and a
trisubstituted oleﬁn (δ 5.35). The data also indicated that sphe-
ciosterol sulfate A (1) contained ﬁve quaternary carbons, 10
methines, and nine methylenes. Interpretation of COSY and HMBC
data allowed the assignment of the A-D steroid ring system. Rings
A and B were assembled on the basis of COSY correlations among
all adjacent protons between H-1R and H-1  and H-8, and
w-coupling correlations from H-8 to H-11. HMBC correlations from
Me-19 to C-1, C-5, C-9, and C-10 completed the structural
assignment of the A and B rings. Rings C and D were assigned on
the basis of HMBC correlations from Me-18 to C-12, C-13, C-14,
and C-17 and from Me-30 to C-8, C-13, C-14, and C-15. HMBC
correlations from H-11 to C-8 and C-12 conﬁrmed the position of
the 9,11-double bond. COSY correlations from H-15 to H-16 and
from H-16 to H-17 completed the structural assignment of the C
and D rings. The structure of the side chain was established using
HMBC correlations from Me-21 to C-17, C-20, and C-22; Me-27
to C-24, C-25, and C-26; and Me-29 to C-24 and C-28. COSY
correlations from H-22a and H-22b to H-23; H-23 to H-24; and
H-24 to H-28 completed the assignment of the molecule.
The relative conﬁguration of spheciosterol sulfate A (1), as
drawn, was determined on the basis of coupling constants and
ROESY data (Figure 1). H-2 and H-3 were deemed equatorial on
the basis of the small coupling between H-1R and H-2 (J ) 4.0
Hz), as well as the w-coupling between H-1  and H-3 observed in
the COSY data. A large coupling constant between H-5 and H-6
Table 1. NMR Data for Spheciosterol Sulfates A-C( 1-3) (500 MHz, CD3OD)
spheciosterol sulfate A (1) spheciosterol sulfate B (2) spheciosterol sulfate C (3)
position δH mult (J, Hz) δC δH mult (J, Hz) δC δH mult (J, Hz) δC
1R 1.85, br dd (14.6, 4.0) 37.2 1.86, br dd (14.7, 3.9) 37.3 1.83 br dd (14.6, 3.9) 37.2
1  2.33, br d (14.6) 2.31, br d (14.7) 2.37, br d (14.6)
2 4.96, m 75.4 4.96, m 75.4 4.99, m 75.5
3 4.83
a 75.8 4.82
a 75.8 4.82
a 76.1
4 4.46, dt (3.1, 1.0) 68.4 4.46, dt (2.8, 1.0) 68.4 4.47, dt (3.0, 1.0) 68.3
5 1.48, dd (11.2, 3.1) 47.7 1.48, dd (11.4, 2.8) 47.7 1.50, dd (11.3, 3.0) 47.8
6 4.84
a 75.7 4.84
a 75.7 4.84
a 76.0
7R 1.55, m 35.3 1.55, m 35.2 1.57, m 35.0
7  2.23, dt (12.0, 4.6) 2.23, dt (11.7, 4.5) 2.24, dt (11.8, 4.6)
8 2.50, br d (12.5) 41.1 2.49, br d (12.9) 41.1 2.51, br d (12.9) 41.1
9 146.5 146.4 146.5
10 39.4 39.7 39.4
11 5.35, br d (5.5) 117.5 5.35, br d (5.2) 117.4 5.35, br d (5.4) 117.3
12R 2.12, br d(17.3) 38.2 2.11, br d (16.8) 38.1 2.10, br d (17.1) 38.2
12  1.94, dd (17.3, 5.5) 1.95, dd (16.8, 5.2) 1.98, dd (16.9, 5.5)
13 45.4 45.4 45.3
14 47.9 47.9 47.9
15R 1.37, m 34.5 1.36, m 34.5 1.39, m 34.7
15  1.43, m 1.45, m 1.47, m
16R 1.89, m 28.6 1.89 28.7 1.92, m 28.9
16  1.32, m 1.31, m 1.33, m
17 1.63, m 52.1 1.63, m 52.0 1.68, m 51.9
18 0.70, s 14.7 0.68, s 14.7 0.70, s 14.7
19 1.42, s 25.2 1.42, s 25.2 1.45, s 25.2
20 1.42, m 36.8 1.34, m 37.6 1.38, m 37.5
21 0.89, d (6.6) 18.5 0.91, d (6.2) 18.9 0.90, br d (6.5) 18.9
22a 1.36, m 34.7 1.38, m 34.6 1.43, m 34.3
22b 0.97, m 0.97, m 1.07, dd (13.3, 6.6)
23a 1.40, m 30.2 1.53, m 30.3 1.57, m 29.2
23b 1.29, m 1.08, m 1.32, m
24 1.87, m 50.6 1.52, m 56.8 1.39, m 40.5
25 148.5 148.4 43.0
26a 4.75, dd (2.5, 1.3) 112.1 4.77, dd (2.5, 1.4) 112.6 154.6
26b 4.66, br d (2.5) 4.62, br d (2.5)
27 1.57, br s 17.6 1.57, br s 18.8 1.70, br s 19.4
28a 1.34, m 27.4 1.52, m 31.1 4.74, dd (2.4, 1.3) 110.0
28b 4.72, br d (2.4)
29 0.82, t (7.3) 12.2 0.81, d (6.2) 21.6 0.97, s 22.8
30 0.80, s 18.5 0.92, d (6.2) 20.9 0.96, s 24.2
31 0.80, s 18.6 0.82, d (6.7) 14.5
32 0.81, s 18.5
a Overlapped with HOD signal.
Figure 1. Key ROE correlations supporting the relative conﬁgu-
ration of spheciosterol sulfate A.
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a small coupling constant between H-4 and H-5 (J ) 3.1 Hz)
suggested that H-4 was equatorial. The large vicinal coupling
between H-5 and H-6 and the ROE effect observed between Me-
19 and H-6 suggested a trans A/B ring juncture. ROE effects
observed from Me-18 to H-8 and H-12  and from Me-30 to H-7R
and H-17 supported a trans-fused C/D ring juncture. Biosynthetic
precedent and ROE effects for H-8 to H-6 and Me-19; Me-19 to
H-1  and H-6; and H-17 to H-12R led to the assignment of
spheciosterol sulfate A (1)a s2 S,3 S,4 R,5 R,6 S,8 S,1 0 S,1 3 R,
14S,1 7 R,2 0 R. The relative conﬁguration of C-24 was not
determined. These data were consistent with the data reported for
topsentiasterol sulfate E (4)
17 and Sch 575867,
18 which contain an
identical steroid nucleus.
The molecular formula for spheciosterol sulfate B (2),
C31H49O13S3Na3, was derived from NMR data and the HRESIMS
ion at m/z 363.12123 ([M - 3Na + H]-2, ∆ 0.01 ppm). Compounds
1, 3, and 4 exhibited sequential losses of 3 Na+ ions on a Micromass
Q-tof micro, supporting the presence of 3 Na in all of the
spheciosterol sulfates’ molecular formulas. Losses of 80 Da in MS/
MS experiments and the presence of multiply charged ions indicated
2 contained three sulfate esters. Initial interpretation of the 1H and
13C NMR data (Table 1) indicated that 2 contained four methyl
singlets (δ 0.68, 0.80, 1.42, 1.57), three methyl doublets (δ 0.81,
0.91, 0.92), four oxygenated methines (δ 4.46, 4.82, 4.84, 4.96), a
terminal oleﬁn (δ 4.77, 4.62), and a trisubstituted oleﬁn (δ 5.35).
The data also indicated that spheciosterol sulfate B (2) contained
ﬁve quaternary carbons, 11 methines, and eight methylenes. After
comparing the NMR data of 1 and 2, it was apparent that
spheciosterol sulfate B (2) contained the same steroid nucleus as
spheciosterol sulfate A (1) with an isopropyl group instead of the
ethyl group present in 1.
The molecular formula for spheciosterol sulfate C (3),
C32H51O13S3Na3, was derived from NMR data and the HRESIMS
ion at m/z 370.12910 ([M - 3Na + H]-2, ∆ + 0.5 ppm). 3 also
exhibited losses of 80 Da and multiply charged ions, signifying
sulfate esters in the molecule. Initial interpretation of the 1H and
13C NMR data (Table 1) indicated that 3 contained six methyl
singlets (δ 0.70, 0.81, 0.96, 0.97, 1.45, 1.70), two methyl doublets
(δ 0.82, 0.90), four oxygenated methines (δ 4.47, 4.82, 4.84, 4.99),
a terminal oleﬁn (δ 4.74, 4.72), and a trisubstituted oleﬁn (δ 5.35).
The data also indicated that spheciosterol sulfate C (3) contained
six quaternary carbons, 10 methines, and eight methylenes.
Comparison of the NMR data between 1, 2, and 3 showed that the
same steroid nucleus was present in 3, along with a slightly different
side chain. The structure of the side chain was established using
HMBC correlations from Me-21 to C-17, C-20, and C-22; Me-27
to C-25, C-26, and C-28; Me-29 and Me-30 to C-24, C-25, C-26,
and to each other; and Me-31 to C-23, C-24, and C-25, which
completed the assignment of spheciosterol sulfate C (3).
The molecular formula for 4,C 31H49O13S3Na3, was derived from
NMR data and the HRESIMS ion at m/z 363.12124 ([M - 3Na +
H]-2, ∆ +0.1 ppm). Interpretation of COSY, HSQC, and HMBC
data allowed for the assignments of all 1H and 13C signals, which
veriﬁed that 4 was the known compound topsentiasterol sulfate E
(4).
17
Spheciosterol sulfates A-C( 1-3) and topsentiasterol sulfate E
(4) inhibited PKC  with IC50 values of 1.59, 0.53, 0.11, and 1.21
µM, respectively. In a cell-based assay using primary human
chondrocytes, 1-4 also inhibited NF-κB activation with EC50 values
of 12-64 µM. These sterols exhibited potent activity against PKC ,
but displayed less of an effect on NF-κB. The side chain appears
to be important for activity against PKC ; spheciosterol sulfate C
(3) is 10-fold more active than spheciosterol sulfate A (1) and
topsentiasterol sulfate E (4).
The spheciosterols are examples of a small group of 4 -hydroxy-
14R-methyl sterols that occur among the wealth of steroids isolated
from marine organisms. Topsentiasterols A-E
17 and Sch 575867
18
are the only previously reported members of the 4 -hydroxy-14R-
methyl sterol group. The ∆9(11)-4,4-demethyl-4-deoxy-14R-methyl
substitution pattern is also rare in marine steroids, observed only
in ibisterol sulfates A-C
4,19 and lembehsterols A and B.
20 In
holothurians, the ∆9(11)-14R-methyl substitution pattern is biosyn-
thesized directly from parkeol (the ∆9(11) isomer of lanosterol) rather
than from lanosterol or cycloartenol.
21 It is likely that sponges utilize
the same pathway.
The proposed biosynthesis for the side chains present in
spheciosterol sulfates A-C( 1-3) and topsentiasterol sulfate E (4)
is shown in Figure 2. The side chains present in 1-4 are likely
formed via methylations by S-adenosylmethionine (SAM) to the
side chain present in parkeol, along with other modiﬁcations.
Following pathway a, an electrophilic methyl equivalent from SAM
is added to the 24,25-double bond, and a Wagner-Meerwein 1,2-
hydride shift generates the 24,28-double bond that can follow
pathway c or d. Pathway c illustrates the addition of another methyl
from SAM to C-28, a loss of a proton to generate the 24,28-double
bond, and isomerization to form the side chain in 1. Pathway d
illustrates the addition of a methyl from SAM to C-28 and a
Wagner-Meerwein 1,2-hydride shift to form the 25,26-double bond
present in the side chain of 1. Pathway c is more likely than d,a s
it generates the side chains of 2 and 4. Pathway e illustrates the
addition of a methyl from SAM to C-28 and a Wagner-Meerwein
Figure 2. Proposed biosynthesis for the side chains present in spheciosterol sulfates A-C( 1-3) and topsentiasterol sulfate E (4).
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chain of 2. Pathway f illustrates the addition of a methyl from SAM
to C-28, nucleophilic attack by the methyl group to close the
cyclopropane ring, and simultaneous loss of a proton to generate
the side chain in 4. Pathway b illustrates the addition of a methyl
from SAM to C-24 and a loss of a proton to form the 25,26-double
bond. Then, SAM adds a methyl twice to C-26, and a loss of a
proton re-forms the 25,26-double bond. Finally, SAM adds a methyl
to C-25, and a loss of a proton generates the 26,28-double bond
present in the side chain of 3.
The side chain present in spheciosterol sulfate A (1) has been
reported from several marine sources, including a few species of
the green alga Codium,
22–25 the green alga UlVa lactuca,
26 the
sponge Echinoclathria subhispida,
27 and an unidentiﬁed chryso-
phyte.
28 The side chain present in spheciosterol sulfate B (2) has
been reported in two different sponges, Dysidea herbacea
29 and
Verongia cauliformis,
30 and an unidentiﬁed chrysophyte.
28 The side
chain present in spheciosterol sulfate C (3) has never been reported.
However, side chains with different oleﬁn patterns have been
reported from sponges of the family Halichondriidae
31–33 and an
unidentiﬁed chrysophyte.
28 The side chain present in topsentiasterol
sulfate E (4) has been reported from the sponges Topsentia sp.
17,19
and Petrosia weinbergi
5 and an unidentiﬁed chrysophyte.
28 Interest-
ingly, the side chains present in 1, 2, and 4 and an isomer of the
side chain in 3 are all present in an unidentiﬁed chrysophyte.
28 In
contrast, the steroid nucleus among the two organisms is different.
Experimental Section
General Experimental Procedures. Optical rotations were measured
on a JASCO DIP-370 digital polarimeter. UV spectra were acquired
in spectroscopy grade MeOH using a Hewlett-Packard 8452A diode
array spectrophotometer. IR spectra were recorded on a JASCO FT/
IR-420 spectrometer. NMR data for 1-4 were collected using a Varian
INOVA 500 (1H 500 MHz, 13C 125 MHz) NMR spectrometer with a
3 mm Nalorac MDBG probe and referenced to residual solvent (δH
3.31, δC 49.15 for CD3OD). High-resolution ESIMS analyses were
performed on either a ThermoFinnigan LTQ-FT or a Micromass Q-tof
micro. Initial puriﬁcation was performed on HP20SS resin. HPLC was
performed on an Agilent 1100 system.
Biological Material. Spheciospongia sp. (Hadromerida, Clionaidae),
sample CDO-00-12-141, was collected by scuba in Cagayan de Oro,
Philippines (09°39.385′ N, 125°23.449′ E); a voucher specimen is
maintained at the University of Utah. This gray olive-green Sphecio-
spongia sp. is a massive sponge with small ﬁstules projecting through
the substrate, with no indication of a boring habit. The ectosome consists
of a moderately dense palisade of discrete, erect bundles of tylostyles
forming a nearly continuous surface skeleton and a thin layer of spiraster
microscleres lying on or near the surface. The choanosomal skeleton
is disorganized, criss-crossed bundles of tylostyles becoming slightly
denser in the center of the sponge. Heavy concentrations of spirasters
are scattered throughout the choanosome and lining of aquiferous canals.
Megascleres: tylostyles not apparently divided into more than one size
category but with size range of 240-720 × 8-17 µm, with moderately
large tylote, occasionally subtylote bases, and tapering to sharp points.
Microscleres: single size class of spiraster, 13-52 µm. This species is
similar in habit and skeletal structure to Spheciospongia Vagabunda
(Ridley, 1884) but with signiﬁcantly larger spicule sizes.
Extraction and Isolation. The Spheciospongia sp. specimen (CDO-
00-12-141) was exhaustively extracted with MeOH to yield 1.2 g of
crude extract. The crude extract was separated on HP20SS resin using
a gradient of H2O to IPA in 25% steps, and a ﬁnal wash of 100%
MeOH, to yield 5 fractions, 15 mL each. The third fraction (50/50
H2O/IPA, 35.4 mg) was chromatographed by HPLC using a Phenom-
enex Onyx C18 monolithic column (100 × 10 mm) employing a gradient
of 20% CH3CN/H2O to 65% CH3CN/H2O at 5 mL/min over 30 min to
yield 6 fractions, 187A-187F. Fraction 187E was further chromato-
graphed by HPLC using an Agilent ZORBAX Eclipse XDB C8 column
and employing a gradient of 2% CH3CN/H2O to 100% CH3CN at 4
mL/min over 45 min to yield 11 fractions, 191A-191K. Fraction 191F
was puriﬁed by HPLC using an Agilent ZORBAX Eclipse XDB C8
column employing a gradient of 30% CH3CN/20 mM NaCl in H2Ot o
50% CH3CN/20 mM NaCl in H2O at 4.5 mL/min over 45 min to
provide spheciosterol sulfate A (1, 0.4 mg) eluting at 25.7 min. Fraction
191G was puriﬁed by HPLC using an Agilent ZORBAX Eclipse XDB
C8 column employing a gradient of 30% CH3CN/20 mM NaCl in H2O
to 50% CH3CN/20 mM NaCl in H2O at 4.5 mL/min over 45 min to
provide spheciosterol sulfate B (2, 1.0 mg) eluting at 28.4 min. Fraction
191H was puriﬁed by HPLC using an Agilent ZORBAX Eclipse XDB
C8 column employing a gradient of 2% CH3CN/0.2 M NaCl in H2Ot o
50% CH3CN/0.2 M NaCl in H2O at 4.5 mL/min over 48 min to provide
topsentiasterol sulfate E (4, 1.3 mg) eluting at 44.9 min and sphecios-
terol sulfate C (3, 1.0 mg) eluting at 45.7 min.
Desalting of HPLC fractions was achieved by extracting the fractions
with 1:1 EtOAc/MeOH, followed by concentration in Vacuo. The
samples were then ﬁltered through C18 Sep-Pak cartridges; salts were
removed by washing with 100% H2O, and individual compounds were
eluted with 100% MeOH.
Spheciosterol sulfate A (1): amorphous, white solid; [R]22
D -34.2
(c 0.02, MeOH); UV (MeOH) λmax (log ε) 206 (3.66) nm; IR (cell)
νmax 2648, 1662, 1242, 933 cm-1; 1H NMR and 13C NMR data, see
Table 1; HRESIMS m/z 757.1984 [M - Na]- (calcd for
C30H47O13S3Na2, 757.1974).
Spheciosterol sulfate B (2): amorphous, white solid; [R]22
D -31.6
(c 0.07, MeOH); UV (MeOH) λmax (log ε) 206 (3.70) nm; IR (cell)
νmax 2644, 1662, 1248, 935 cm-1; 1H NMR and 13C NMR data, see
Table 1; HRESIMS m/z 363.12123 [M - 3Na + H]-2 (calcd for
C31H50O13S3, 363.12123).
Spheciosterol sulfate C (3): amorphous, white solid; [R]22
D -36.0
(c 0.07, MeOH); UV (MeOH) λmax (log ε) 204 (3.62) nm; IR (cell)
νmax 2648, 1662, 1244, 931 cm-1; 1H NMR and 13C NMR data, see
Table 1; HRESIMS m/z 370.12910 [M - 3Na + H]-2 (calcd for
C32H52O13S3, 370.12905).
Topsentiasterol sulfate E (4): amorphous, white solid; [R]D +58.3
(c 0.10, MeOH); UV (MeOH) λmax (log ε) 204 (3.60) nm; IR (ﬁlm)
νmax 3460, 2930, 1650, 1220 cm-1;
17 1H NMR and 13C NMR data see
Supplemental Table 1; HRESIMS m/z 363.12124 [M - 3Na + H]-2
(calcd for C31H50O13S3, 363.12123).
PKC LanthaScreen Assay. The compounds were dissolved in
100% DMSO and tested at different concentrations in an in Vitro PKC 
TR-FRET-based LanthaScreen assay (Invitrogen) to determine IC50
values. The assay consisted of full-length PKC  (Invitrogen), a
ﬂuorophore-labeled custom PKC  substrate peptide (SynPep), and ATP
(Sigma), which were added sequentially to the serially diluted
compounds in assay plates. The optimized ﬁnal concentrations of the
constituents were 1× compound, 6.25% DMSO, 0.2 µM peptide, 15
µM ATP (at 1× Km), and 80 pM PKC . The ﬁnal volume of the enzyme
reaction was 10 µL performed in black, low-volume, 384-well
polypropylene MatriPlates (Matrical). The enzyme reaction was stopped
with 5 µL of 60 mM EDTA after 1 h incubation at rt. Tb-pSer-PKC
antibody (Invitrogen) made up in TR-FRET buffer (Invitrogen) was
used for detection. The ﬁnal concentrations of EDTA and Tb-antibody
were 15 mM and 1 nM, respectively. The plates were read using
Envision after 30 min of incubation at rt. Staurosporine was used as
the positive control for the assay. Signal:background noise was
determined, and a dose-response curve was generated for the
compounds from which the IC50 was determined using an XLFit
inhibition model.
NF-KB Assay. Fresh human cartilage samples from OA patients
undergoing knee replacement surgeries were obtained from New
England Baptist Hospital, Boston, MA, with patient consent. Harvested
cartilage pieces were sliced into 2 mm pieces in growth medium
consisting of D-MEM/F12 (Gibco, Carlsbad, CA) + 1% antimycotic
antibiotic solution (Sigma, St. Louis, MO) + 10% FBS (Sigma), washed
twice with PBS, and treated with 1 mg/mL Pronase (Roche, India-
napolis, IN) at 37 °Cf o r1hi ngrowth media. Cartilage pieces were
washed with media twice and treated with 0.25 mg/mL collagenase
(Roche) at 37 °C for 14-15 h in serum-free media. The cell suspension
was ﬁltered through a 70 µm nylon cell strainer (BD Falcon, Bedford,
MA), centrifuged, washed, and resuspended in growth media. Cells
were counted on a hemocytometer. Cell viability was determined by
trypan blue dye exclusion and was found to be g95%.
NF-κB activation was tested by the commercial FACE NF-κB p65
proﬁler (Active Motif, Carlsbad, CA) following the manufacturer’s
protocol for primary cells. Optimal conditions for using primary
chondrocytes to test NF-κB activation in response to cytokine (
inhibitors were determined empirically. The conditions found to be
optimal were plating density of 30 000 cells/well, 10 ng/mL IL-1 
1216 Journal of Natural Products, 2008, Vol. 71, No. 7 Whitson et al.concentration, 2 h preincubation with inhibitors prior to cytokine
induction, and 3 h incubation with cytokine before performing the assay.
Brieﬂy, human osteoarthritic primary chondrocytes were harvested and
seeded into the 96-well ELISA plate from the kit. Inhibitors were added
to the wells at various concentrations and incubated for2ha t3 7°C.
After this incubation, IL-1 was added and allowed to incubate for 3 h
at 37 °C. After stimulation of the NF-κB pathway, the cells were ﬁxed
in order to preserve activation-speciﬁc protein modiﬁcations followed
by running the NF-κB p65 ELISA.
Cytotoxicity testing was performed for each of the inhibitors at the
concentrations used in the NF-κB assay either by measuring lactate
levels in culture media as a measure of cellular metabolism and viability
using a kit from Sigma or by directly measuring cellular proliferation
using the WST-1 assay (Roche). The EC50 values were determined from
the dose-response curves of the signal:background ratio in an XLFit
inhibition model.
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